MRS2 and cancer: After we reported that Fuc-Hpt is a promising biomarker for pancreatic cancer, many researchers have reported increases in Fuc-Hpt in sera of patients with different cancers such as colon cancer [24], liver cancer [25], lung cancer [26], and pancreatic cancer [27].